Product Images Erlotinib

This appears to be the label information for Erlotinib Tablets. The tablets are film-coated and contain 100mg of erlotinib free base. The label provides the usual dosage, storage requirements, and includes a barcode for tracking. The tablets are distributed by Areva Pharmaceuticals, Inc. in Georgetown, IN.*

This is a description for a prescription drug called Erlotinib, it contains 30 tablets and each coated tablet contains 0mg of Erlotinib. The drug should be stored at a temperature below 25°C and comes with a complete prescribing information. The NDC number for the drug is 89923-726-30.*

This is a product label for Erlotinib Tablets manufactured by Areva Pharmaceuticals. The tablet contains 150mg of erlotinib free base and is intended for use as directed by a physician. It includes storage instructions and the drug's National Drug Code (NDC) number. The label also features a color logo with guidelines on how to print it.*

This is a medicine labeled as Erlotinib with a dose of 150 mg per tablet. The tablets are coated and packaged in a container of 30 tablets. The usual dosage and complete prescribing information are included in the package insert. The medicine should be stored between 15°C to 30°C (59°F to 86°F). The medicine is distributed by Areva Pharmaceuticals, Inc. with product code TSDRUGS/112013. No further information is available due to the low-quality text.*

This table shows the survival probability of patients taking either Placebo or Erlotinib, along with the number of patients at risk. The columns represent the survival probability of the patients in percentages, ranging from 0 to 100. The rows represent the number of patients at risk. The table also includes the overall survival of patients in months, with different time intervals shown in the last row.*

This appears to be data from a clinical trial comparing the efficacy of a drug called "Erotinb" to a placebo in terms of overall survival (measured in months) for patients with a certain medical condition. The data provides a breakdown of the number of patients at risk over time for both groups. However, without further context, it's difficult to provide a more detailed description or interpretation of the results.*